{"id":112716,"date":"2009-05-18T12:45:19","date_gmt":"2009-05-18T16:45:19","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/rexin-g-controls-tumor-growth-and-improves-survival-in-chemotherapy-resistant-sarcoma-and-osteosarcoma-phase-i-ii-and-phase-ii-studies-asco-2009\/"},"modified":"2009-05-18T12:45:19","modified_gmt":"2009-05-18T16:45:19","slug":"rexin-g-controls-tumor-growth-and-improves-survival-in-chemotherapy-resistant-sarcoma-and-osteosarcoma-phase-i-ii-and-phase-ii-studies-asco-2009","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/rexin-g-controls-tumor-growth-and-improves-survival-in-chemotherapy-resistant-sarcoma-and-osteosarcoma-phase-i-ii-and-phase-ii-studies-asco-2009\/","title":{"rendered":"Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I\/II and Phase II Studies, ASCO 2009"},"content":{"rendered":"

NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong><\/p>\n

SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies (epeiusbiotech.com<\/a>) today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I\/II studies and a Phase II confirmatory trial in the U.S.<\/p>\n

\"Epeius\"The Phase I\/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic bone and soft tissue sarcomas (ASCO Annual Meeting 2009, #10513) demonstrated that Rexin-G was well-tolerated with no dose-limiting toxicity. Moreover, Rexin-G exhibited dose-dependent efficacy in terms of tumor control rates, progression-free survival, and overall survival, thus validating both the efficiency of the tumor-targeting technology and the pharmacological mechanisms of action.<\/p>\n

The efficacy and safety of Rexin-G was further confirmed in a Phase II study for chemotherapy-resistant osteosarcoma. Again, in the absence of dose-limiting toxicity, Rexin-G was demonstrated to control tumor growth, prolong progression-free survival, and improve overall survival in osteosarcoma patients who have failed known therapies. It is important to note that these outstanding results, were achieved when Rexin-G was administered as monotherapy-unlike many other so-called targeted biologics where one or more toxic agents are used in combination in order to achieve even marginal results. <\/p>\n

Based on a critical analysis of its performance in the clinic, the U.S. FDA recently granted Rexin-G Orphan Drug Status for both soft tissue sarcoma and osteosarcoma. <\/p>\n

The results of these studies will be presented by Dr. Sant P. Chawla, Sarcoma Oncology Center, Santa Monica CA, and discussed by Dr. Katherine Janeway, Dana-Farber Cancer Institute, Boston MA on Saturday, May 30, 2009 at 5:00 p.m. EST\/EDT. <\/p>\n

About Epeius Biotechnologies<\/strong><\/p>\n

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its high-performance gene delivery systems that are embodied in Rexin-G and Reximmune-C, a tumor-targeted cancer vaccine. <\/p>\n

To learn more about ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com, or visit: www.epeiusbiotech.com<\/a>.<\/p>\n

News issued by: Epeius Biotechnologies Corporation<\/p>\n

\"Epeius<\/p>\n

Original Image: https:\/\/www.send2press.com\/wire\/images\/09-0418-Epeius_72dpi.jpg<\/a><\/small><\/p>\n

# # # <\/p>\n

Original Story ID: (4990) :: 2009-05-0518-002<\/small><\/p>\n

Original Keywords: Epeius Biotechnologies Corporation, Rexin-G Orphan Drug Status for both soft tissue sarcoma and osteosarcoma, Dr. Erlinda M. Gordon, ASCO Annual Meeting 2009 Epeius Biotechnologies Corporation <\/small><\/p>\n

NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong> | Published: 2009-05-18 12:45:19<\/p>\n","protected":false},"excerpt":{"rendered":"

SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I\/II studies and a Phase II confirmatory trial in the U.S.<\/p>\n","protected":false},"author":9780,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"singles-wide.php","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19937],"tags":[],"class_list":["post-112716","post","type-post","status-publish","format-standard","hentry","category-press-releases-archive","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":461,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/112716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/9780"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=112716"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/112716\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=112716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=112716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=112716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}